Clinical trials: Posterior Uveitis
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Noninfectious Posterior Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00407082
- Testing
- fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch & Lomb Incorporated
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to…
- Trial name
- NCT00468871
- Testing
- fluocinolone acetonide intravitreal implant, corticosteroids and immunosuppressants
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
VKH Syndrome
Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH
Vogt-Koyanagi-Harada (VKH) disease is a rare autoimmune disorder characterized by bilateral ocular inflammation that may lead to serous retinal detachment and permanent visual impairment if not promptly treated.
- Trial name
- VKH-OC (NCT07405489)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Benha University
Uveitis
Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A
Study efficacy of everolimus on course of uveitis: obtain quiescence of inflammation after start of treatment duration to obtain quiescence of inflammation number of patients with quiescence of inflammation
- Trial name
- NCT00803816
- Testing
- everolimus
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Carsten Heinz
Uveitis
Daclizumab and Sirolimus to Treat Uveitis
This study will examine whether the combination of the drugs daclizumab and sirolimus can effectively treat adults with uveitis, an eye inflammation.
- Trial name
- NCT00078689
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Edema, Cystoid, Uveitis
Vascular Endothelial Growth Factor (VEGF) in Uveitis
This study will look for the presence in blood of a substance called vascular endothelial growth factor (VEGF) in patients with uveitis (eye inflammation).
- Trial name
- NCT00001738
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis
ANTI-TAC THERAPY FOR UVEITIS
Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects.
- Trial name
- NCT00001526
- Testing
- Daclizumab (Zenapax)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Uveitis, Posterior, Vasculitis Retinal
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.
- Trial name
- NCT03066869
- Testing
- H.P. ACTHAR GEL
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ocular Immunology and Uveitis Foundation
Tuberculosis (TB), Uveitis
Six-months Versus Nine-months ATT for Ocular TB
The goal of this clinical trial is to learn if 6-months anti-TB therapy is not worse than 9-months therapy for the treatment of tubercular posterior uveitis.
- Conditions
- Tuberculosis (TB), Uveitis, Retinal Vasculitis, Choroiditis
- Trial name
- NCT06613919
- Testing
- Anti-Tuberculosis Treatment
- Where
- 3 sites in Burma, India and 1 more
- Volunteers
- 58 people
- Sponsor
- L.V. Prasad Eye Institute
Uveitis, Posterior, Uveitis, Intermediate
Ozurdex Monotherapy Trial
This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- OM (NCT05101928)
- Testing
- Ozurdex 0.7mg Ophthalmic Implant, Prednisone
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Deep Retinal Capillary Ischemia, Paracentral Acute Middle Maculopathy
Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma
To investigate the efficacy of retinal electromagnetic stimulation and sub-tenon autologous platelet rich plasma in the treatment of deep retinal capillary ischemia.
- Conditions
- Deep Retinal Capillary Ischemia, Paracentral Acute Middle Maculopathy, Acute Macular Neuroretinopathy
- Trial name
- rEMS (NCT04242719)
- Testing
- Electromagnetic stimulation, Platelet rich plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Ankara Universitesi Teknokent
Central Serous Chorioretinopathy, Irvine-Gass Syndrome
Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.
- Conditions
- Central Serous Chorioretinopathy, Irvine-Gass Syndrome, Pars Planitis, Cystoid Macular Edema
- Trial name
- NCT05337332
- Testing
- Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Benha University
Uveitis, Posterior, Glaucoma
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP)…
- Trial name
- NCT00570479
- Testing
- anecortave acetate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Texas Retina Associates
Intermediate Uveitis, Posterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
- Trial name
- NCT00333814
- Testing
- Dexamethasone
- Where
- 18 sites in United States, Australia and 16 more
- Volunteers
- 229 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
A Long-Term Safety Study of OZURDEX® in Clinical Practice
This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or…
- Conditions
- Retinal Vein Occlusion, Macular Edema, Uveitis, Posterior
- Trial name
- NCT01539577
- Testing
- dexamethasone 700 μg intravitreal implant
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 875 people
- Sponsor
- Allergan
Noninfectious Intermediate, Posterior, or Panuveitis
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time.
- Trial name
- NCT07861074
- Testing
- Tulisokibart, Background prednisone therapy
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC